Canadian Agency for Drugs and Technologies in Health

Agence canadienne des médicaments et des technologies de la santé

Supporting Informed Decisions

HTA

USER GUIDE — Indirect Treatment Comparison

MARCH 2009

Publications can be requested from:

Canadian Agency for Drugs and Technologies in Health
600–865 Carling Avenue, Ottawa ON Canada K1S 5S8
Telephone: 613–226–2553 • Fax: 613–226–5392 • E-mail: pubs@cadth.ca
www.cadth.ca • www.acmcts.ca

www.cadth.ca
The software described in this user manual was developed by George Wells, Shagufta A. Sultan, Li Chen, Maryam Khan, and Doug Coyle.

References to the software can be cited as: Wells GA, Sultan SA, Chen L, Khan M, Coyle D. Indirect treatment comparison [computer program]. Version 1.0. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2009.

Further reference to the appropriate use of this software can be found in the CADTH Report Wells GA, Sultan SA, Chen L, Khan M, Coyle D. Indirect evidence: indirect treatment comparisons in meta-analysis. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2009.

We would like to thank Jenny Mehan for writing the user manual.

NOTICE

THIS IS A DISCLAIMER. PLEASE READ IT CAREFULLY. THE FOLLOWING DISCLAIMER APPLIES TO THE SOFTWARE PROGRAM AND ASSOCIATED DOCUMENTATION. IN ORDER TO USE THE SOFTWARE PROGRAM, YOU MUST AGREE TO THE SUBSTANTIALLY SIMILAR DOCUMENT PRESENTED TO YOU BEFORE RUNNING THE SOFTWARE.

1. LICENCE

1.1 Subject to the terms and conditions of this Agreement, the Canadian Agency for Drugs and Technologies in Health (the “Licensor”) grants to You a non-exclusive, non-transferable licence to use the Software Program contained on the media associated with this Indirect Treatment Comparison User Guide (the "User Guide") for your own internal use in connection with viewing the report. The Software Program and its related documentation, including but not limited to this User Guide, are together referred to as the "Licenced Program".

2. PROTECTION AND SECURITY OF LICENCED PROGRAMS

2.1 Except as expressly provided herein, You shall not use, print, copy, translate, adapt, create derivative works from, record, transmit, display, disclose, publish, encumber by way of security interest or otherwise, pledge or transfer, assign, distribute or otherwise deal with the Licenced Program in whole or in part.

2.2 You shall refrain from and shall prevent others from reverse assembling, decompiling or applying any procedure to the Licenced Program in order to derive and/or appropriate for use, the source code or source listings for the Licenced Program.

3. No WARRANTIES

THE LICENCED PROGRAM IS PROVIDED FREE OF CHARGE AND “AS IS” WITHOUT ANY WARRANTY WHATSOEVER. YOU ASSUME ALL RISKS AND RESPONSIBILITIES FOR SELECTION OF THE LICENCED PROGRAM TO ACHIEVE YOUR INTENDED
RESULTS, AND FOR THE INSTALLATION OF, USE OF AND RESULTS OBTAINED FROM THE LICENCED PROGRAM. THE COMPANY MAKES NO WARRANTY THAT THE LICENCED PROGRAM WILL BE ERROR FREE OR FREE FROM INTERRUPTION OR FAILURE. TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, LICENSOR DISCLAIMS ALL WARRANTIES, EITHER EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO, WARRANTIES OR REPRESENTATIONS OF WORKMANSHIP, SUITABILITY OR FITNESS FOR A PARTICULAR PURPOSE, DURABILITY, AND NONINFRINGEMENT WITH RESPECT TO THE LICENCED PROGRAM. WITHOUT LIMITING THE GENERALITY OF THE FOREGOING, LICENSOR DOES NOT WARRANT THAT THE LICENCED PROGRAM WILL MEET ALL OF YOUR NEEDS OR THAT OPERATION OF THE LICENCED PROGRAM WILL BE ERROR-FREE. LICENSOR EXPRESSLY DISCLAIMS ANY EXPRESS OR IMPLIED WARRANTY REGARDING SYSTEM AND/OR SOFTWARE AVAILABILITY, ACCESSIBILITY, OR PERFORMANCE.

4. LIMITATIONS ON LIABILITY

TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, IN NO EVENT WILL LICENSOR OR ITS SUPPLIERS OR LICENSORS BE LIABLE FOR ANY DAMAGES WHATSOEVER (INCLUDING, WITHOUT LIMITATION, DAMAGES FOR LOSS OF BUSINESS PROFITS, BUSINESS INTERRUPTION, LOSS OF BUSINESS INFORMATION, LOSS OF GOODWILL; WORK STOPPAGE; HARDWARE OR SOFTWARE FAILURE, OR OTHER PECUNIARY LOSS) ARISING OUT OF THE USE OR INABILITY TO USE THE LICENCED PROGRAM.

4.2 In no event whatsoever, regardless of the form OR CAUSE of action WHETHER IN CONTRACT OR TORT or the number of claims asserted, and whether in respect of a breach or default in the nature of a breach of condition or fundamental term or of a fundamental breach OR AS A RESULT OF NEGLIGENCE shall Licensor be liable for any claims made by You. Licensor shall not be liable for indirect or consequential damages. YOU ASSUME THE ENTIRE COST OF ANY DAMAGE RESULTING FROM YOUR USE OF THE LICENCED PROGRAM AND THE INFORMATION CONTAINED IN OR COMPILED BY THE LICENCED PROGRAM.

4.3 Licensor shall not be liable in any way whatsoever, whether as a result of a claim or action in contract or tort OR OTHERWISE for any indirect, special or consequential damages OR FOR lost profits or lost business revenue, lost business, failure to realize expected savings, or other commercial or economic loss of any kind whatsoever, or FOR any damages, direct or indirect, special or consequential arising out of any claim against You by any person whether or not such damages WERE foreseeable and whether or not Licensor HAD been advised of the possibility of such COSTS, LOSSES OR damages.

5. GENERAL

5.1 The Term of this Agreement shall continue from the date of acceptance to the date at which You remove the Licenced Program from your computer. Section 4 herein shall survive termination of this Agreement.
5.2 This Agreement shall be governed by and construed in accordance with the laws of the Province of Ontario. Any dispute between You and Licensor regarding this Agreement will be subject to the exclusive venue of Ottawa, Ontario. This Agreement is the entire agreement between You and Licensor and supersedes any other communications or advertising with respect to the Licensed Program and documentation. If any provision of this Licence is held to be unenforceable that provision shall be severed from this Licence and shall be replaced with a provision which is legally enforceable which reflects the intention of the parties to the maximum extent possible and the remainder of this Licence shall continue in full force and effect.

6. CONTACT INFORMATION

Should You have any questions concerning this Agreement, or if You desire to contact Licensor for any reason, please contact htainfo@cadth.ca.

This document is the property of the Canadian Agency for Drugs and Technologies in Health. Materials published in this document may only be copied or used for non-commercial purposes within your organization. No other use of this information is permitted.

Copyright © 2009 CADTH
Version 3.0, March 2009
# TABLE OF CONTENTS

## ABOUT THIS GUIDE

- Introduction .................................................................................................................................. ii
- Audience ....................................................................................................................................... ii
- Conventions .................................................................................................................................. ii
- Related Documentation ................................................................................................................ ii
- Technical Support ......................................................................................................................... ii

## 1 INTRODUCTION

1.1 Overview................................................................................................................................ 1
  1.1.1 Introduction......................................................................................................................... 1
  1.1.2 In this chapter..................................................................................................................... 1

1.2 Indirect Treatment Comparison............................................................................................. 1
  1.2.1 Background ....................................................................................................................... 1
  1.2.2 Methodology ...................................................................................................................... 1

## 2 USING THE ITC APPLICATION

2.1 Overview................................................................................................................................ 2
  2.1.1 Introduction......................................................................................................................... 2
  2.1.2 In this chapter..................................................................................................................... 2

2.2 Starting the ITC Application ................................................................................................... 2
  2.2.1 Introduction......................................................................................................................... 2

2.3 User Interface .......................................................................................................................... 2
  2.3.1 Introduction......................................................................................................................... 2
  2.3.2 Screen 1: Main window ..................................................................................................... 3
  2.3.3 Effect measure .................................................................................................................. 4
  2.3.4 Number of treatments ........................................................................................................ 4
  2.3.5 Toolbars ............................................................................................................................ 5
  2.3.6 Screen 2: Requested weights window .............................................................................. 5
  2.3.7 Toolbar .............................................................................................................................. 6

## 3 EXAMPLE

3.1 Overview................................................................................................................................ 7
  3.1.1 Introduction......................................................................................................................... 7
  3.1.2 In this chapter..................................................................................................................... 7

3.2 Overview................................................................................................................................ 7

3.3 Step 1: Effect Measure and Number of Treatments ......................................................... 8

3.4 Step 2: Comparing Alendronate with Placebo ................................................................. 9

3.5 Step 2a: Weighted Effect Measure (1,2) .............................................................................. 10

3.6 Step 3: Comparing Etidronate with Placebo ..................................................................... 11

3.7 Step 3a: Weighted Effect Measure (2,3) .............................................................................. 12

3.8 Step 4: Calculating Results ................................................................................................. 13

## 4 GLOSSARY ................................................................................................................................. 14
ABOUT THIS GUIDE

Introduction

The ITC User Guide has been prepared to assist in the use of the ITC application. It describes:

- The theory behind the development of the ITC application
- The components of the ITC application
- A detailed example of use.

Audience

This user guide assumes that the user is familiar with the theory and methodology surrounding indirect treatment comparisons.

Conventions

The conventions used in this document are:

**NOTE**

Means “Reader, take note.” Notes contain helpful suggestions or background information.

**CAUTION**

Means “Reader, be careful. Loss of data can result from your actions.”

**HINT**

Alerts the reader to a helpful tip, suggestion, or example.

Related Documentation

Wells GA, Sultan SA, Chen L, Khan M, Coyle D. *Indirect evidence: indirect treatment comparisons in meta-analysis*. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2009.

Technical Support

For assistance with the ITC application, please contact your designated support person.
# INTRODUCTION

## Overview

### Introduction

This chapter provides background information about indirect treatment comparisons and an introduction to the methodology behind the ITC application.

### In this chapter

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Background</td>
<td>1</td>
</tr>
<tr>
<td>Methodology</td>
<td>1</td>
</tr>
</tbody>
</table>

## Indirect Treatment Comparison

### Background

When comparing treatment interventions, the need for indirect approaches is increasing. A direct assessment of interventions A and B is available if a randomized controlled trial of A versus B has been conducted. However, many competing interventions have not been compared directly and/or such direct evidence is limited and insufficient. The reasons for lack of a direct comparison vary.

More complex indirect evidence settings can arise. In the next simplest setting, we may have direct evidence from A versus C, B versus D, and C versus D. Using this evidence, we can attempt an indirect comparison of A versus B using, in particular, the direct evidence of C versus D. Even in the situation of A versus C, B versus C, D versus C, and D versus F, treatment F can be an important contributor to the indirect comparison of A versus B. The web of direct and indirect evidence can be complex.

Within this web of evidence, there is often a need to synthesize evidence from randomized controlled trials, and methods for deriving indirect treatment comparisons using meta-analysis are of prime interest.

### Methodology

The Bucher et al. (1997) method has been widely used for making indirect comparisons. The approach is pragmatic, and the assumption of independence among trials often holds in settings where the direct comparison between treatments is not available and one needs to use results (possibly from meta-analysis) from non-overlapping treatment pairs. These indirect approaches have recently been applied in published meta-analyses by Yazdanpanah et al. (2004) and Lim et al. (2003).
For discrete outcomes, expanding the indirect odds ratio approach by Bucher et al. (1997) for more complex webs of evidence involving any number of direct comparisons was considered. This generalized approach was then considered for the relative risk (RR), hazard ratio, risk difference, and mean difference. The ITC software application has been developed to assist analysts in applying this expanded approach.

2 USING THE ITC APPLICATION

2.1 Overview

2.1.1 Introduction

This chapter introduces the user interface and basic functionality of the ITC application.

2.1.2 In this chapter

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Starting the ITC Application</td>
<td>2</td>
</tr>
<tr>
<td>User Interface: Main Window</td>
<td>3</td>
</tr>
<tr>
<td>User Interface: Requested Weights Window</td>
<td>5</td>
</tr>
</tbody>
</table>

2.2 Starting the ITC Application

2.2.1 Introduction

The ITC application is launched either from the disk or from your desktop.

- Locate and double-click the ITC application icon.

2.3 User Interface

2.3.1 Introduction

The ITC application has been developed in Visual Basic to assist with various calculations associated with indirect comparisons.
When entering data, you can tab from one cell to the next.

2.3.2 Screen 1: Main window

The ITC application consists of two windows. On the first window, the effect measure of interest is identified. Information for each consecutive pair of treatments is entered in terms of the point estimate and 95% confidence interval (CI) of the effect measure for each direct comparison involved in the indirect comparison. The resulting indirect comparison estimates for the effect measure and the 95% CI as well as the P value for the test of association corresponding to this effect measure are provided.

![Figure 1: Main Window](image-url)
2.3.3 Effect measure

- The desired Effect measure is chosen by selecting the corresponding option button.

![Indirect Treatment Comparisons]

2.3.4 Number of treatments

- The Number of Treatments (k) is entered by typing directly in the appropriate field or by using the arrows to scroll to the desired value. The highest number you may enter is 10.
- For each consecutive pair of treatments, provide the direct estimates of the measure of association and the 95% lower confidence limit (95% LCL) and 95% upper confidence limit (95% UCL).

The order of entry of the treatment pairs must follow the exact sequence indicated with the bridging comparison groups linking the treatment pairs.

- To reverse the order of a treatment comparison, select the appropriate checkbox.

For example, if 1 = Treatment A, 2 = Treatment B, and 3 = Treatment C, then (1,2) is (A,B), and for (2,3) we can enter (C,B) and use the reverse option to switch it to (B,C). This option can be useful when B is a placebo and the results are given as the active treatment versus placebo (i.e., A versus Placebo[B] and C versus Placebo[B]).
2.3.5 Toolbars

The toolbars on the main window allow you to calculate, clear, import, and save your data as well as exit the application.

<table>
<thead>
<tr>
<th>Button</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calculate</td>
<td>When all data has been entered, returns the desired calculations.</td>
</tr>
<tr>
<td>Clear</td>
<td>Clears all data from the main window.</td>
</tr>
<tr>
<td>Save</td>
<td>Allows the user to save the data (*.txt file).</td>
</tr>
<tr>
<td>Open</td>
<td>Allows the user to import previously saved data.</td>
</tr>
<tr>
<td>Exit</td>
<td>Closes the application without saving the data.</td>
</tr>
</tbody>
</table>

2.3.6 Screen 2: Requested weights window

If the test of association is needed, the weights used for the calculation of each weighted average estimate from the main window are required for its calculation. The requested weights window is accessed by clicking the arrow to the right of the corresponding information for each consecutive pair of treatments.
The requested weights window calculates the weighted effect measure for the direct comparison on the main window. These weights are needed to calculate the test statistic for the test of association. There are various formats in which the information to calculate these weights can be provided, and these formats are identified through the weight selections (direct versus derived; fixed versus random), and the specific information for each study involved in the direct comparison is then identified and requested.

- For a direct treatment \((i, i + 1)\), enter the number of studies on which the estimate is based by typing directly in the corresponding field or by using the arrows to scroll to the desired value. The highest number you may enter is 20.

- The desired Weight is chosen by selecting the corresponding option button.
  - The option is available to enter the weights directly. In particular, if the effect estimate is based on one study, then a single weight of 1 can be entered.
  - The weights can also be computed from first principles, based on the frequencies (for RR, odds ratio, and risk difference) or the standard errors (for mean difference), using either the fixed or random effects model, or the general inverse method.

**Figure 2: Requested Weights Window**

<table>
<thead>
<tr>
<th>Button</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Close</td>
<td>Saves data and closes the window.</td>
</tr>
<tr>
<td>Clear</td>
<td>Clears all data from the window.</td>
</tr>
</tbody>
</table>
3 EXAMPLE

3.1 Overview

3.1.1 Introduction

This chapter provides an in-depth walk-through of a worked example detailing the clinical-effectiveness of pharmacological interventions for preventing fractures.

3.1.2 In this chapter

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overview</td>
<td>7</td>
</tr>
<tr>
<td>Step 1: Effect Measure and Number of Treatments</td>
<td>8</td>
</tr>
<tr>
<td>Step 2: Comparing Alendronate with Placebo</td>
<td>9</td>
</tr>
<tr>
<td>Step 2a: Weighted Effect Measure (1,2)</td>
<td>10</td>
</tr>
<tr>
<td>Step 3: Comparing Etidronate with Placebo</td>
<td>11</td>
</tr>
<tr>
<td>Step 3a: Weighted Effect Measure (2,3)</td>
<td>12</td>
</tr>
<tr>
<td>Step 4: Calculating Results</td>
<td>13</td>
</tr>
</tbody>
</table>

3.2 Overview

Osteoporosis is associated with important medical, social, and financial implications, and its incidence is expected to increase significantly as the Canadian population ages. Many of the consequences of osteoporosis are potentially lessened through the use of a number of non-pharmacological and pharmacological interventions. The oral bisphosphonate drugs etidronate, alendronate, and risedronate have been introduced as pharmacological options for the primary and secondary prevention of osteoporotic fractures.

We have conducted a systematic review assessing the clinical-effectiveness of etidronate, alendronate, and risedronate in the primary and secondary prevention of osteoporotic fractures in postmenopausal women receiving these agents compared with untreated women over a follow-up period of at least one year. A systematic literature search of the evidence from randomized placebo-controlled trials of each of the three drugs was conducted using a standardized Cochrane Collaboration approach to literature search, article selection, data extraction, and quality assessment. Clinical data analysis was conducted according to the methodology of the Cochrane Collaboration for systematic reviews and meta-analyses.

Considering the data available for the longest treatment duration in the trials and using the follow-up denominators for the number of patients in the trial, a detailed worked example will be considered. For this detailed worked example, the weighted RR effect estimates of fracture after treatment with the bisphosphonates alendronate and etidronate compared with placebo will be used to derive an indirect estimate. The indirect treatment comparison method will be used to evaluate the head-to-head comparison of alendronate to etidronate, using the placebo as the bridging group in the one-step comparison (i.e., k = 3).
3.3 Step 1: Effect Measure and Number of Treatments

In the main window, the effect measure of interest is identified, and information for each consecutive pair of treatments of interest is requested in terms of the point estimate and 95% CI of the effect measure for each direct comparison involved in the indirect comparison.

The effect measure of interest is the **Relative Risk (RR)**, which is chosen by selecting the corresponding option button.

There are three treatments involved in this indirect comparison — alendronate, etidronate, and placebo — and the number 3 is entered in the **Number of Treatments** field.

For each consecutive pair of treatments, the direct estimates of the measure of association and the 95% LCL and UCL must be provided. The order of entry of the treatment pairs must follow the exact sequence indicated with the bridging comparison groups linking the treatment pairs. The interest here is to compare alendronate with placebo and then placebo with etidronate and, in so doing, use placebo as the bridging comparison group.
3.4 Step 2: Comparing Alendronate with Placebo

A systematic review was conducted for trials that compared alendronate with placebo for primary or secondary prevention. Non-vertebral fractures were reported in eight trials. One trial did not report fractures separately by treatment groups, and one trial reported that no fractures occurred in either treatment group.

The pooled estimate of the RR of non-vertebral fractures from the five trials that could be analyzed demonstrated a significant reduction (16%) in non-vertebral fractures (RR: 0.84 [95% CI 0.74 to 0.94]).

The direct estimate from this meta-analysis for the RR (0.84) and the 95% lower confidence limit (0.74) and 95% upper confidence limit (0.94) are entered on the first direct comparison line (1 = alendronate, 2 = placebo).

To request the weights used for calculating the weighted effect measure for the direct comparison, the arrow to the right of the (1,2) line is clicked. If the test of association is not of interest, this step can be skipped.
3.5 Step 2a: Weighted Effect Measure (1,2)

The pooled estimate of the RR of non-vertebral fractures (RR 0.84, 95% CI 0.74 to 0.94) was based on five trials. To calculate the weights that were used for this weighted RR risk, the Derived option and the Fixed effect option are selected because heterogeneity was not an issue.

Rates for the treatment and control groups for each study are requested in the form of numerator (number of events) / denominator (number of subjects). From the systematic review:

<table>
<thead>
<tr>
<th>Treatment (n/N)</th>
<th>Control (n/N)</th>
</tr>
</thead>
<tbody>
<tr>
<td>122/1022</td>
<td>148/1005</td>
</tr>
<tr>
<td>261/2214</td>
<td>294/2218</td>
</tr>
<tr>
<td>3/46</td>
<td>1/45</td>
</tr>
<tr>
<td>45/500</td>
<td>38/332</td>
</tr>
<tr>
<td>19/792</td>
<td>37/841</td>
</tr>
</tbody>
</table>

These results are entered in the corresponding lines provided. Click Close to save the entries and close the window.
3.6 Step 3: Comparing Etidronate with Placebo

A systematic review was conducted for trials that compared etidronate with placebo for primary or secondary prevention. Non-vertebral fractures were reported in seven trials.

The pooled estimate of the RR of non-vertebral fractures from the seven trials indicated a lack of effect of etidronate on non-vertebral fractures. The 95% CI around the RR estimate for all non-vertebral fractures was wide with a relative risk reduction of approximately 32% and a relative risk reduction increase of 42% (RR 0.95, 95% CI 0.66 to 1.36). Results were consistent across the seven trials.

The direct estimate from this meta-analysis for the RR (0.95) and the 95% lower confidence limit (0.66) and 95% upper confidence limit (1.36) are entered on the second direct comparison. The results entered compare etidronate with placebo. By selecting **Reverse**, the results will be reversed so placebo is compared with etidronate and the (2,3) will correspond to (2 = placebo, 3 = etidronate).

To request the weights used for calculating the weighted effect measure for the direct comparison, the arrow to the right of the (2,3) line is clicked. If the test of association is not of interest, this step can be skipped.
3.7 Step 3a: Weighted Effect Measure (2,3)

The pooled estimate of the RR of non-vertebral fractures (RR 0.95, 95% CI 0.66 to 1.36) was based on seven trials. To calculate the weights that were used for this weighted RR, the Derived option and the Fixed effect option are selected because heterogeneity was not an issue.

Rates for the treatment and control groups for each study are requested in the form of numerator (number of events) / denominator (number of subjects). From the systematic review:

<table>
<thead>
<tr>
<th>Treatment (n/N)</th>
<th>Control (n/N)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3/39</td>
<td>5/35</td>
</tr>
<tr>
<td>2/25</td>
<td>3/24</td>
</tr>
<tr>
<td>3/45</td>
<td>6/46</td>
</tr>
<tr>
<td>5/20</td>
<td>6/20</td>
</tr>
<tr>
<td>20/92</td>
<td>16/89</td>
</tr>
<tr>
<td>14/93</td>
<td>12/89</td>
</tr>
<tr>
<td>1/14</td>
<td>1/14</td>
</tr>
</tbody>
</table>

These results are entered in the corresponding lines provided. Click Close to save the entries and close the window.
3.8 Step 4: Calculating Results

Once all the data are entered, the resulting indirect comparison estimates for the effect measure and the 95% CI as well as the P value for the test of association corresponding to this effect measure are provided in the main window for the comparison of treatments (1,3) using treatment 2 as the bridging comparison.

When all data is entered, click **Calculate**.

The indirect treatment effect estimate for the RR of alendronate compared with etidronate was 0.88 with the 95% CI (0.60 to 1.29). The result indicates that alendronate and etidronate are not significantly different. This is confirmed with the P value for the test of association of 0.79.

To save these results to a .txt file, click **Save**.
4 GLOSSARY

CI confidence interval
ITC Indirect Treatment Comparison
LCL lower confidence limit
OR odds ratio
RR relative risk
UCL upper confidence limit